

Abstract:

Topic: COVID in HSCT and Haemato-oncology Patients

Covid-19 pandemic results in serious mortality and morbidity worldwide, patients with hematological malignancies are the most severely affected cohort, in addition to greatly elevated risk of severe Covid-19 and high mortality, the pandemic has affected the timely diagnosis, treatment and follow-up in hematological malignancy. There are still inadequate big randomized clinical trials to guide scientifically proven management plan for this group of patients, many recommendations are extrapolated from data and clinical trials of non-cancer population, in addition to logical inference from the understanding of immunological dysregulation and pathophysiology of Covid-19. With more experience and information coming in, Hematologists must use existing and updated data to plan and manage patients with hematological malignancies to achieve the balance between inadequate treatment of underlying disease and predispose patients to more severe Covid-19 if they are infected during treatment.